Everest Lifesciences

Everest Medicines is a commercial-stage biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Greater China and other emerging Asia Pacific markets. Founded in 2017 by CBC Group, the company has built a diverse portfolio through a strategic in-licensing model, targeting high-unmet-need areas such as renal diseases, infectious diseases, and immunology. Its lead product, Nefecon, is a first-in-disease treatment for IgA nephropathy, while Xerava provides a potent option for multi-drug resistant infections. Everest also maintains a proprietary mRNA technology platform and a state-of-the-art manufacturing facility in Jiashan, China, to support its long-term R&D and production goals.